Neoadjuvant BRAF-Directed Therapy Is Associated with Favorable Surgical and Survival Outcomes in Patients with BRAF-Mutated Anaplastic Thyroid Cancer

Clinical Thyroidology®Vol. 35, No. 5 Thyroid CancerNeoadjuvant BRAF-Directed Therapy Is Associated with Favorable Surgical and Survival Outcomes in Patients with BRAF-Mutated Anaplastic Thyroid CancerShejil Kumar, Matti L Gild, and Venessa TsangShejil Kumar Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia.Search for more papers by this author, Matti L Gild Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia. Faculty of Medicine and Health Sciences, University of Sydney, Sydney, New South Wales, Australia.Search for more papers by this author, and Venessa Tsang Department of Diabetes, Endocrinology & Metabolism, Royal North Shore Hospital, Sydney, New South Wales, Australia. Faculty of Medicine and Health Sciences, University of Sydney, Sydney, New South Wales, Australia.Search for more papers by this authorPublished Online:12 May 2023https://doi.org/10.1089/ct.2023;35.208-211AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 35Issue 5May 2023 Information© Copyright 2023, Mary Ann Liebert, Inc.To cite this article:Shejil Kumar, Matti L Gild, and Venessa Tsang.Neoadjuvant BRAF-Directed Therapy Is Associated with Favorable Surgical and Survival Outcomes in Patients with BRAF-Mutated Anaplastic Thyroid Cancer.Clinical Thyroidology®.May 2023.208-211.http://doi.org/10.1089/ct.2023;35.208-211Published in Volume: 35 Issue 5: May 12, 2023PDF download